In the aftermath of the Covid-19 pandemic, there was a debate both on the limits of typical on-site monitoring visits and on whether alternative technology-based solutions should continue to be used, even under normal conditions. As known during the pandemic, the...
Exom Group Srl, in collaboration with Meteda Srl, announces the release of Genius FIRE Diabetes, the first large-scale eSource infrastructure operating in Europe for more efficient conduction of Clinical Trials in Diabetes. As is well known, Diabetes is one of the...
Crises are rare periods in history when need stimulates the search for innovative solutions and accelerates the timing to start adopting them. Given the enormous investments that the life sciences industry makes in drug development, it is not surprising that...
Although industry 4.0 has so far been the most advanced of all industrial revolutions, it is in no way the last frontier. Industry 5.0 is already on the horizon. Below you will see how it will impact clinical research. The risk of infection and the difficulties in...
Exom Group is proud to announce that the results of CARAVAGGIO, a practice-changing study, have been presented at the ACC Virtual 2020 and published on the NEJM on March 29th, 2020. DOI: 10.1056/NEJMoa1915103 The study involved 159 clinical sites distributed in 9...
The clinical trials sector is going through a challenging and delicate phase, that could lead to a slowdown in drug development in general. In an attempt to limit damage, safeguard the validity of the data and protect the health of patients by guaranteeing their...
Global Health & Pharma Excellence AwardsAward Winner 2022
Exom is proud to announce that Global Health & Pharma has awarded us the 2022 Global Excellence Award as "Most innovative Full-Service CRO - 2022" for our pioneering, cutting-edge use of technology in clinical trials to support study stakeholders.
